Atlanta, GA Clinical Trials Report — July 2026

Atlanta participants should act quickly on studies approaching their enrollment deadlines: 73 recruiting trials are expected to close within the next 90 days, including 12 that accept healthy volunteers. Atlanta currently has 1,408 recruiting trials across 533 research facilities, giving patients and volunteers a broad local choice—but projected closing dates can change if studies reach enrollment targets sooner.

July brought 15 new trials, down from 28 in May and 28 in June. The city’s recruiting pipeline remains active, with opportunities spanning cancer, neurological disease, metabolic conditions, mental health, caregiving, infectious disease prevention, and pediatric research.

Closing-soon studies include cancer, stroke, lupus, and depression

People affected by the following conditions may want to review eligibility and contact Atlanta research teams now:

• Stroke (3 trials)
• Head and neck squamous cell carcinoma (2 trials)
• Lupus nephritis (2 trials)
• Acute myeloid leukemia (2 trials)
• Major depressive disorder (2 trials)
• Hematologic malignancy (2 trials)
• Aging, advanced solid tumor, acute lymphoblastic leukemia, and amputation or wound care (1 each)

The closing list includes both treatment-focused studies and research involving serious or chronic conditions. Healthy volunteers are represented among 12 of these 73 studies. Atlanta has 120 healthy-volunteer trials recruiting overall, so people without a diagnosed condition may still find alternatives if a closing study is not a match. Screening can include age requirements, medication restrictions, health checks, and time commitments.

Major late-stage studies open in Atlanta

Several July openings are notable for their Phase 2 or Phase 3 design, large planned enrollment, or recognized sponsors. The new-trial mix includes 7 drug studies, 6 classified as other, 3 biological studies, 2 behavioral studies, and 1 device study.

• NCT07735637 is AstraZeneca’s Phase 3 DURGA-6 study, comparing consolidation treatment with AZD0120 against autologous stem-cell transplant in transplant-eligible people newly diagnosed with multiple myeloma. Planned enrollment is 750 participants.
• NCT07686263 is a Phase 3 relapse-prevention study of KarXT in schizophrenia, sponsored by Karuna Therapeutics, a Bristol Myers Squibb company. It plans to enroll 472 participants.
• NCT07702578 is a Phase 3 study sponsored by TScan Therapeutics evaluating T-cell receptor-engineered donor T cells after allogeneic stem-cell transplantation. Planned enrollment is 310 participants.
• NCT07728123, sponsored by Westat, is Screen2Prevent, a broad implementation study evaluating targeted and universally offered HIV screening approaches in emergency departments. The study plans to include 84,000 participants.
• NCT07696338 is the REACT study of early airway-clearance therapies for people with cystic fibrosis, including hypertonic saline and dornase alfa approaches. Planned enrollment is 405 participants.
• NCT07704060 is the Phase 2 IN-HOME study from KDH Research & Communication, examining outreach from trained community health workers to improve male informal caregivers’ knowledge, skills, attitudes, and confidence. Planned enrollment is 360 participants.

Other new July categories include adults with overweight or obesity and type 2 diabetes, Alzheimer’s disease and related disorders, acute myeloid leukemia, anterior cruciate ligament tears, aplastic anemia, brain tumors, brainstem glioma, bone marrow failure syndromes, and caregiver research. AstraZeneca sponsors 2 of the new studies; Emory University, Jazz Pharmaceuticals, Dren Bio, BrainChild Bio, Arthroresearch, and other organizations sponsor one each.

Emory-affiliated sites offer the deepest local access

Atlanta’s largest concentration of recruiting research is within the Emory network, making its hospitals and cancer programs the most practical starting points for many patients. Emory University leads with 202 trials. Emory University Hospital/Winship Cancer Institute has 129, followed by Emory University Hospital Midtown with 120.

• Emory University (202 trials)
• Emory University Hospital/Winship Cancer Institute (129 trials)
• Emory University Hospital Midtown (120 trials)
• Emory University Hospital (88 trials)
• Emory Saint Joseph’s Hospital (85 trials)
• Children’s Healthcare of Atlanta (54 trials)
• Northside Hospital (49 trials)
• Grady Health System (47 trials)
• Emory University School of Medicine (45 trials)
• Research Site (42 trials)
• Children’s Healthcare of Atlanta – Arthur M. Blank Hospital (38 trials)
• Winship Cancer Institute, Emory University (31 trials)

These locations collectively cover oncology, blood disorders, neurology, psychiatry, infectious disease, cardiology, pediatrics, and other specialties. Children’s Healthcare of Atlanta and Arthur M. Blank Hospital are especially relevant for families seeking pediatric studies, while Winship-affiliated sites provide concentrated cancer and hematologic research options.

Healthy volunteers and eligibility this month

Of July’s 15 new trials, 3 accept healthy volunteers. Four include children, one is female-only, one is male-only, and 12 include older adults. This range creates opportunities for people who do not have the condition under study, as well as for families and older participants, but every study uses its own screening criteria.

Industry sponsors account for 11 of the new studies, while four are categorized as other. People interested in joining should ask whether Atlanta enrollment is currently open, what visits are required, whether compensation is available, and whether travel assistance is offered. Those affected by a closing-soon condition and healthy volunteers should contact sites first, since enrollment may end before the listed 90-day window.

Other Georgia cities to consider

Participants willing to travel can also search nearby Georgia locations. Recruiting trials are listed in Decatur (5), Savannah (3), Athens, Augusta, Macon, and Marietta (2 each), as well as Jonesboro and Kennesaw (1 each). Atlanta remains the state’s largest reported hub in this dataset, but these cities may offer a useful alternative when a local study has narrow eligibility or is nearing capacity.

New openings declined across the recent monthly trend, from 28 in February to 26 in March, 23 in April, 31 in May, 28 in June, and 15 in July; the dataset also lists three openings for August. As summer enrollment develops, Atlanta patients and volunteers should monitor Emory, Winship, Children’s Healthcare, Northside, Grady, and nearby Georgia sites for newly activated studies and changing availability.